Polpharma a new member of ScanBalt
We are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia. For over 80 years, we have been trusted by patients, healthcare professionals and business partners alike.
We are among the top 20 generic drug manufacturers in the world. We employ more than 7,500 people in Poland and on international markets. We have 7 manufacturing plants in Poland, Russia and Kazakhstan, and 7 research and development centres. Polpharma Group’s portfolio includes about 600 products, and another 200 are being developed.
We manufacture a wide range of prescription drugs and pharmaceuticals for in-patient care. We have a leading share in the key therapeutic areas in Poland. We specialize in pharmaceutical preparations used in cardiology, gastroenterology and neurology. Over the counter medications (OTC) account for a significant part of our product portfolio. In addition, our offer comprises dietary supplements, medical devices, cosmetic products and phyto-pharmaceuticals. We develop our operations in the field of biotechnological drugs: biosimilars. We are also one of the largest Polish manufacturers of active pharmaceutical ingredients (APIs) which compete successfully in the developed markets of the EU and the US.
We provide drugs of the highest quality and reliable medical knowledge. We are one of the most innovative companies in Poland according to the ranking prepared by the Institute of Economic Sciences of the Polish Academy of Sciences (PAN). We contribute to scientific development and health education and promotion.
17 August 2018
Call for General Assembly ScanBalt fmba
15 August 2018
Innovation for Health (Rotterdam)